Research to Promote Longevity and Health Span in Companion Dogs: A Pediatric Perspective

"Research to Promote Longevity and Health Span in Companion Dogs: A Pediatric Perspective." The American Journal of Bioethics, 18(10), pp. 64–65

This article refers to:

A Randomized Trial of Rapamycin to Increase Longevity and Healthspan in Companion Animals: Navigating the Boundary Between Protections for Animal Research and Human Subjects Research

Acknowledgments

This publication was supported in part by the National Center For Advancing Translational Sciences under Award Number UL1 TR002319 and the National Institute of Aging under award U19 AG057377. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health

Conflicts of Interest

Kate E. Creevy declares she is an officer and stockholder in Fido-Gen, Inc, a start-up company which seeXks to provide disease-risk profiles for dogs, based on their genetic map and age. She is a paid consultant for IDEXX, Inc, a reference laboratory for veterinary medicine. Neither of these relationships influenced this work in any way. Daniel Promislow declares he is co-founder and owner of Fido-Gen, Inc. Matt Kaeberlein declares he is a co-founder and has stock in Fido-Gen, Inc., a companion animal genetics/genomics company. ▪